1. Andrews, L. B., & Paradise, J. (2005). Gene patents: The need for bioethics scrutiny and legal change. Yale Journal Health Policy Law & Ethics, 5(1), 403–412, 407.
2. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576. (2013).
3. Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576. 2, Graff, G. D., Phillips, D., Lei, Z., Oh, S., Nottenburg, C., & Pardey, P. G. (2013). Not quite a myriad of gene patents. Nature Biotechnology, 31(404–410), 409.
4. Bagley, M. A. (2003). Patent first, ask questions later: Morality and biotechnology in patent law. Wm & Mary Law Review, 45, 469–548.
5. Bagley, M. A. (2017a). De-materializing genetic resources: Synthetic biology, intellectual property and the ABS bypass. In C. R. McManis & B. Ong (Eds.), Routledge handbook of biodiversity and the law. Routledge.